Asthma is a chronic disease characterized by persistent pulmonary inflammation, episodic bronchoconstriction, and airway remodeling that affects more than 300 million people worldwide. The current therapeutic approach to asthma is based on long-term treatments. Most asthmatic patients need multiple medications daily and for long periods of time, in some cases for life.

We offer a new therapeutic approach: treating patients with asthma with autologous monocyte-derived Macrophages (Macs) in which PLA2G5, a master regulator of inflammation,  has been removed using CRISPR technology.

Our long-term goal is to improve transplantation therapy to cure chronic diseases, including asthma, lung cancer, and COPD.